What the U.S. can learn from India's rapid coronavirus testing efforts


India scaled up its coronavirus testing over a two-month period starting in June by relying on faster, cheaper antigen tests. At first glance, that's a positive development and a strategy the United States is also considering as the pandemic continues, The Associated Press reports. At the same time, however, there's a sense that India has become overly reliant on the antigen tests, which are also less accurate than slower, more expensive lab tests.
The problem isn't the antigen tests themselves since their shortcomings are well understood. Rather, India seemingly hasn't been retesting enough patients who have tested negative even though the country's health officials are recommending the practice, particularly for those who have symptoms. Between June 18 and July 29, court documents reportedly show that in Delhi state only 0.5 percent, or 1,365 of the more than 260,000 people who tested negative, were retested. Plus, there's been a decline in use of more precise lab tests, the figure falling from 11,000 per day to just 5,400.
Dr. Ashish Jha, director of Harvard University's Global Health Institute, said combining data from the two types of tests shouldn't be used to determine that infections are going down in India since using less accurate tests will automatically drive the numbers south, especially if retesting is limited. Going forward, large countries struggling with outbreaks like the U.S. and India will likely need to strike a balance between speed and precision by continuing to rely on accurate lab tests and get retested regularly when using antigen tests. Read more at The Associated Press.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Delhi's dogs earn Supreme Court reprieve
IN THE SPOTLIGHT After an outcry from the public and animal rights activists, India's Supreme Court walks back a controversial plan to round the city's stray dog population into shelters
-
8 hotels with ace tennis courts
The Week Recommends Bring your A game
-
Abrego released from jail, faces Uganda deportation
Speed Read The wrongly deported Kilmar Abrego García is expected to be detained at an ICE check-in and deported to Uganda
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC